<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxygen carriers as alternatives to red blood cell transfusion</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxygen carriers as alternatives to red blood cell transfusion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Oxygen carriers as alternatives to red blood cell transfusion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joy L Fridey, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynne Uhl, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alternatives to red blood cell transfusion have been long-anticipated and sought-after developments in biotechnology and medicine. It is generally understood that a manufactured substance cannot carry out the numerous and complex functions of blood, but terms such as "artificial blood" or "blood substitutes" remain popular with the media and the public. Research efforts have been directed toward products that perform the oxygen-carrying and other transport functions of red blood cells. These products are referred to as oxygen carriers (OCs) or oxygen therapeutics (OTs).</p><p>This article will provide history and rationale for oxygen carriers, clinical information and the status of selected products, and will processes for obtaining products under enhanced access [<a href="#rid1">1-3</a>].</p><p>Red blood cell transfusion and other aspects of tissue oxygen delivery are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>Indications for transfusion (newborns) – (See  <a class="medical medical_review" href="/z/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Indications for transfusion (infants and children) – (See  <a class="medical medical_review" href="/z/d/html/5910.html" rel="external">"Red blood cell transfusion in infants and children: Indications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Indications for transfusion (adults) – (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Indications for transfusion (critically ill) – (See  <a class="medical medical_review" href="/z/d/html/1615.html" rel="external">"Use of blood products in the critically ill"</a> and  <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">"Massive blood transfusion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Normal hemoglobin function – (See  <a class="medical medical_review" href="/z/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen delivery – (See  <a class="medical medical_review" href="/z/d/html/1623.html" rel="external">"Oxygen delivery and consumption"</a> and  <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">HISTORY OF OC DEVELOPMENT</span><span class="headingEndMark"> — </span>Attempts to develop substances that could replace blood date to the 17<sup>th</sup> century and continued into the mid-1800s when hemoglobin solutions were infused experimentally into humans [<a href="#rid4">4,5</a>]. These infusions resulted in significant morbidity and mortality, mostly from nephrotoxic effects of free hemoglobin and red blood cell stroma [<a href="#rid6">6</a>]. This discouraged further activity of consequence, but research was renewed as wars raised awareness that an easily stored, transportable, and abundant OC could be an important medical therapeutic. </p><p>The HIV epidemic was a watershed phenomenon that catalyzed early modern research in the 1980s and propelled the search for such a product to then-peak levels in the 1990s and 2000s. Additional factors that contributed to renewed interest included concerns about other transfusion-transmitted pathogens, immunologic complications of allogeneic transfusion, the need for pretransfusion compatibility testing such as crossmatching, and special storage requirements. (See  <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing"</a> and  <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">"Immunologic transfusion reactions"</a>.)</p><p>While efforts to develop OCs were underway, infectious risks of transfusion from known pathogens declined due to improvements in blood donor screening and testing. This reduction in infectious risk, as well as simultaneous efforts to develop pathogen inactivation technologies, may have impacted perceptions about the need for OCs. However, in a survey sponsored by a biotechnology company specializing in blood pathogen inactivation, at least 84 percent of 502 Americans surveyed essentially still perceived blood as a threat to patient safety [<a href="#rid7">7</a>]. A public health problem that may continue to drive development of these products is the challenge of persistent blood shortages in the United States and globally. It is projected that by the year 2030 there could be a shortfall of 4 million units annually in the United States [<a href="#rid8">8,9</a>]. The worldwide need is for over 200 million units per year in countries that lack testing and storage capabilities to support an allogeneic blood supply [<a href="#rid10">10</a>]. Severe blood shortages associated with the coronavirus disease 2019 (COVID-19) pandemic prompted a new appeal for an OC [<a href="#rid11">11</a>]. </p><p>At the turn of the 21<sup>st</sup> century, there was optimism that rapidly advancing technology would imminently lead to OCs for a variety of clinical settings. Several products advanced to phase III clinical trials but reports of adverse events and regulatory concerns about safety led to trial terminations. Allegations that some companies may have misled investors or withheld outcome results, and the inability to obtain regulatory approval and sustain investor support also resulted in product withdrawals [<a href="#rid12">12,13</a>]. In 2009, the two then-remaining companies filed for bankruptcy and discontinued manufacturing activities.</p><p>Despite these setbacks, the need for oxygen therapeutics remains, and work continues in the field. No OCs are currently licensed by the US Food and Drug Administration (FDA) for use in the United States, with the exception of an unlicensed product, Hemopure, available through enhanced access for specific indications. However, new insights into the basic biology and physiology of hemoglobin and gas transport systems are informing the development of products and potential applications.</p><p class="headingAnchor" id="H3"><span class="h1">CHARACTERISTICS OF AN IDEAL OC</span><span class="headingEndMark"> — </span>An ideal substance for carrying (and delivering) oxygen would have the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid availability</p><p class="bulletIndent1"><span class="glyph">●</span>Effective oxygen-carrying capacity and provision of volume expansion</p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate physiologic interaction with nitric oxide (NO)</p><p class="bulletIndent1"><span class="glyph">●</span>Sterility (absence of pathogens) to the extent possible</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal side effects</p><p class="bulletIndent1"><span class="glyph">●</span>Viability over a range of storage temperatures</p><p class="bulletIndent1"><span class="glyph">●</span>Extended shelf life</p><p class="bulletIndent1"><span class="glyph">●</span>Universal compatibility and elimination of crossmatching</p><p class="bulletIndent1"><span class="glyph">●</span>Cost effectiveness</p><p class="bulletIndent1"><span class="glyph">●</span>Adequate inventory levels</p><p></p><p>An additional benefit would be the ability of chemically or genetically modified products to work in special and specific clinical situations, mentioned below.</p><p class="headingAnchor" id="H4"><span class="h1">CATEGORIES OF OXYGEN CARRIERS</span><span class="headingEndMark"> — </span>Historically, two major categories of OC have been developed:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin-based oxygen carriers (HBOCs)</p><p class="bulletIndent1"><span class="glyph">●</span>Perfluorocarbons (PFCs)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Hemoglobin-based oxygen carriers</span><span class="headingEndMark"> — </span>Mammalian sources for hemoglobin used in HBOCs include bovine (cow), porcine (pig), and human blood, the latter primarily from outdated red blood cell (RBC) units. </p><p>Hemoglobin is separated from RBC stroma through ultrafiltration and purification [<a href="#rid14">14</a>]. It may then be further modified by polymerization, crosslinking, pyridoxylation, encapsulation, and/or pegylation (addition of polyethylene glycol [PEG] molecules), which prevent the dissociation of hemoglobin from its native four-chain configuration into its basic alpha-beta dimers [<a href="#rid15">15</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymerization</strong> – Polymerization of some HBOC converts the four-chain hemoglobin moiety into larger two-to-four hemoglobin molecule-containing polymers [<a href="#rid16">16</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crosslinking</strong> – Crosslinking of alpha chains prevents dissociation of the hemoglobin molecule into alpha-beta dimers, which, with a molecular weight of 34,000, would otherwise be small enough for glomerular filtration and causing nephrotoxicity and hemoglobinuria.</p><p></p><p class="bulletIndent1">Polymerization and crosslinking appeared to have addressed some of the problems associated with unmodified stroma-free hemoglobin. Half-life increased from a few hours to 12 to 48 hours [<a href="#rid17">17</a>]; glomerular filtration decreased, reducing or effectively eliminating nephrotoxicity; oxygenation was improved as a result of lowered oxygen affinity of some products (eg, P50 as high as 54 mmHg) [<a href="#rid15">15,18,19</a>]. However, trials of one of the crosslinked products were associated with increased mortality; consequently, development of at least one HBOC formulation was terminated [<a href="#rid20">20-22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbon monoxide to reduce vasoconstriction</strong> – A product in which carbon monoxide molecules were added to prevent nitric oxide (NO) binding by hemoglobin could reduce vasoconstriction [<a href="#rid23">23</a>]. This might reduce vasoconstriction associated with sickle cell disease. (See <a class="local">'HBOC-associated side effects'</a> below and  <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microparticle delivery</strong> – Nanoparticle or microparticle delivery platforms to deliver hemoglobin have been developed [<a href="#rid24">24</a>]. Liposome-encapsulated hemoglobin (LEH) seemed to confer advantages such as a longer intravascular half-life and the potential for freeze-dried storage [<a href="#rid17">17</a>]. Significant immunologic reactions, mostly due to interactions with the liposomal membrane, stalled the development of this OC [<a href="#rid25">25-27</a>]. However, there is continuing interest in hemoglobin that is encapsulated in other moieties [<a href="#rid28">28-30</a>].</p><p></p><p>Hemoglobin has also been produced through recombinant technology. This approach showed promise in the early 1990s and involved the use of <em>E. coli</em> transfected with human hemoglobin genes. In animal models, however, vasoconstriction attributed to scavenging of nitric oxide by the recombinant product and elevated amylase and lipase levels were observed, suggesting decreased pancreatic perfusion [<a href="#rid31">31-33</a>]. Early efforts on recombinant hemoglobin products were abandoned in 2003, but renewed interest is occurring due to improved biophysical and biochemical insights [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Perfluorocarbons</span><span class="headingEndMark"> — </span>Perfluorocarbon (PFC) products were among the earliest of the 20<sup>th</sup> Century OCs. A 1960s-era magazine depicted a memorable photograph of a breathing rodent submerged in a beaker of PFC, introducing the possibility that an oxygen-carrying liquid could have clinical applications [<a href="#rid35">35</a>].</p><p>PFCs are inert compounds in which fluorine replaces hydrogen atoms. Water insolubility necessitates emulsification, for which egg yolk phospholipid was used in canine (dog) trials [<a href="#rid36">36</a>]. PFCs have a plasma half-life of approximately 12 hours. They were deemed stable for up to two years under refrigeration at approximately 4°C [<a href="#rid14">14</a>].</p><p>Unlike HBOCs, PFCs do not carry and release gases, but because of their decreased surface tension and intramolecular action, they act as highly efficient solvents and have the capability of absorbing significant amounts of gas [<a href="#rid14">14,17,36</a>]. Their oxygen-carrying capacity is linearly related to the PO<sub>2</sub>, and patients receiving these agents could require high concentrations of supplemental oxygen.</p><p class="bulletIndent1"><span class="glyph">●</span>In 1989 the US Food and Drug Administration (FDA) approved the PFC Fluosol for perfusion of ischemic tissues in the setting of percutaneous transluminal coronary angioplasty. This was the first such product ever licensed [<a href="#rid37">37</a>]. Fluosol was withdrawn from the market in 1994 due to lack of commercial success. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results of a randomized trial from Europe of perflubron emulsion in non-cardiac patients suggested that, when used in conjunction with acute normovolemic hemodilution, there were slightly decreased requirements for allogeneic blood versus the control group [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial of the PFC Oxycyte to improve oxygen delivery in traumatic brain injury was halted in 2014 due to low enrollment [<a href="#rid39">39,40</a>].</p><p></p><p>Clinical trials of PFCs as alternates to RBC transfusion are not actively taking place in the United States. This does not preclude future investigations, as at least one agent, Vidophor (formerly Perftoran), which is used outside the United States, may be awaiting trials [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H7"><span class="h1">POTENTIAL USES FOR OCs</span><span class="headingEndMark"> — </span>The clinical areas for which OCs were originally considered to have the greatest potential were cardiovascular elective surgery and hemorrhagic shock related to trauma and acute blood loss.</p><p class="headingAnchor" id="H8"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>In the surgical setting, the goal of clinical trials had been to postpone, reduce, or eliminate the need for allogeneic blood transfusions, especially in cardiovascular procedures (including priming of the bypass pump) and situations in which bleeding could exceed anticipated levels [<a href="#rid14">14,42</a>]. In some studies, patients who received hemoglobin-based oxygen carriers (HBOCs) for cardiac, aortic, or emergency surgery required substantially fewer allogeneic red blood cell (RBC) units compared with controls [<a href="#rid43">43-45</a>].</p><p class="headingAnchor" id="H15033255"><span class="h2">Hemorrhagic shock</span><span class="headingEndMark"> — </span>Because animal data suggested that the outcome of hemorrhagic shock correlated with tissue hypoxia, it was hypothesized that in humans, acellular oxygen-carrying resuscitation fluids could improve outcomes related to hemorrhagic shock in trauma or acute blood loss when blood was not immediately available [<a href="#rid46">46,47</a>]. </p><p>In preclinical studies, hemoglobin solutions and perfluorochemical (PFC) compounds were used to resuscitate animals with severe hemorrhagic shock. These compounds appeared to result in more rapid restoration of normal tissue metabolism and improved survival over crystalloid or colloid solutions [<a href="#rid48">48-50</a>].</p><p>However, the apparently beneficial effects of OCs observed in animals were not replicated in at least two human trauma trials.</p><p class="bulletIndent1"><span class="glyph">●</span>In a 1999 trial, 112 patients with traumatic hemorrhagic shock and unstable vital signs were randomly assigned to receive either diaspirin crosslinked hemoglobin solution or <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> [<a href="#rid21">21</a>]. Patients who received the OC had significantly higher mortality at 2 and 28 days (46 versus 17 percent at 28 days). The mechanism by which diaspirin crosslinked hemoglobin might have worsened outcomes is unclear but may have been related to its actions as a nitric oxide scavenger and/or its vasoconstrictive effects, which may have accelerated the rate of hemorrhage [<a href="#rid51">51</a>]. (See <a class="local">'HBOC-associated side effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2009 multicenter trial, 714 patients with hypotensive injuries (systolic blood pressure ≤90 mmHg) were randomly assigned to receive a human polymerized hemoglobin preparation or crystalloid. Subgroup analysis showed that the experimental OC was associated with significantly higher 30-day mortality and a higher incidence of coagulopathy and myocardial infarction in blunt trauma patients. </p><p></p><p>Concerns have frequently been raised about whether participants in trauma studies would be able to provide informed consent to receive an OC [<a href="#rid52">52-54</a>]. These ethical considerations may continue to inform the design of trials for trauma and other hemorrhaging patients, including those in pre-hospital treatment settings, who may not be able to provide informed consent prior to infusion.</p><p class="headingAnchor" id="H3872858083"><span class="h2">Oxygen therapeutics as bridging agents in acute anemia</span><span class="headingEndMark"> — </span>Although adverse events and other challenges have discouraged or prevented OC clinical trials for trauma patients, case reports have suggested that OCs could potentially provide a stabilizing or interim benefit to patients with acute anemia, thus serving as oxygen-bridging agents. </p><p>Such clinical situations, discussed below, may involve acutely anemic patients for whom human blood is not an option (BNAO) because of religious convictions (eg, Jehovah's Witnesses, who may accept an OC) [<a href="#rid55">55-64</a>]. Other settings in which this may apply is for patients for whom compatible blood is not available, or situations in which blood is not available due to unavailability or severe shortage [<a href="#rid11">11</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>An exsanguinating patient with hemolytic anemia likely was saved by the infusion of an HBOC [<a href="#rid17">17,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with sickle cell disease and acute chest syndrome who had a delayed hemolytic transfusion reaction and hyperhemolysis attributed to two high-frequency antigens (anti-N and anti-Do<sup>a</sup>) was treated with multiple modalities that included <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a>, steroids, intravenous iron, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), and <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a>; the patient also received HBOC-201, which was believed to possibly play a lifesaving role [<a href="#rid66">66</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other reports have described Jehovah's Witnesses who were successfully managed by treatment with a PFC or an HBOC in settings such as trauma, severe postoperative anemia, acute chest syndrome, abruptio placenta, or chemotherapy-induced anemia [<a href="#rid57">57,59-62,67,68</a>]. (See  <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other examples are listed below. (See <a class="local">'Resources and processes for obtaining OCs in the United States'</a> below.)</p><p></p><p>Further discussion regarding the use of OCs in these settings is discussed below and in a separate topic review. (See <a class="local">'Resources and processes for obtaining OCs in the United States'</a> below and  <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Improve oxygen delivery'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Other potential applications</span><span class="headingEndMark"> — </span>The size of HBOCs and PFCs compared with RBCs (&lt;0.1 versus 7 microns, respectively) could theoretically allow OCs to facilitate oxygen transport to poorly oxygenated areas that are not accessible to RBCs [<a href="#rid14">14</a>]. The potential to reach these tissues led to optimism that such products could be used in vaso-occlusive episodes such as stroke and acute pain events associated with sickle cell disease [<a href="#rid69">69,70</a>]. The availability of such products could be especially important in sickle cell disease if compatible blood is not available in a timely way for a patient with multiple or rare RBC alloantibodies [<a href="#rid71">71</a>]. It has also been proposed that the radiation- and chemo-sensitivity of some tumors could be enhanced by OCs, one of which had been under development for this purpose [<a href="#rid72">72</a>].</p><p>The relatively brief intravascular activity of OC makes it unlikely that these agents will replace RBC transfusions for patients with long-term or chronic transfusion needs.</p><p class="headingAnchor" id="H1528833015"><span class="h1">RESOURCES AND PROCESSES FOR OBTAINING OCs IN THE UNITED STATES</span></p><p class="headingAnchor" id="H3204734660"><span class="h2">Feasibility of obtaining OCs</span><span class="headingEndMark"> — </span>If an unlicensed OC is available under a US Food and Drug Administration (FDA) Expanded Access protocol, it may be possible to obtain products for life-threatening anemia in some patient populations such as those for whom blood is not an option (BNAO), as demonstrated by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymerized bovine hemoglobin</strong> – A 2010 case report described a Jehovah's Witness (JW) with acute lymphoblastic leukemia (ALL) who was successfully treated for life-threatening anemia with 15 units of a hemoglobin-based oxygen carrier (HBOC) consisting of polymerized bovine hemoglobin (HBOC-201; Hemopure) [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1">A 2013 case report described the successful two-unit transfusion of HBOC-201 for a 19-year-old JW with warm autoimmune hemolytic anemia (AIHA) and a hemoglobin of 2.8 g/dL [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">A 2018 case report described successful use of an HBOC in three individuals with sickle cell disease, two of whom could not receive blood because they were JWs and one for whom compatible blood could not be found due to the presence of alloantibodies [<a href="#rid75">75</a>]; all had nadir hemoglobin levels &lt;6 g/dL (two were &lt;4 g/dL). Infusion of the OC enabled sufficient recovery and discharge from the hospital. Two of the individuals developed methemoglobinemia requiring treatment with ascorbic acid and two experienced transient hypertension.</p><p></p><p class="bulletIndent1">A 2020 retrospective observational study included 10 acutely anemic patients for whom blood was not an option who received 10 to 27 units of HBOC-201 over 5 to 14 days between 2014 and 2017. Most patients declined blood because of religious convictions. All survived, but the authors cautioned that this survival rate may not be assumed in all situations and could depend on underlying patient conditions. The main adverse effects were elevation in blood pressure and methemoglobinemia, for which management approaches were described. Transient adverse events included gastrointestinal effects, volume overload, liver enzyme elevations, and decreases in oxygen saturation by pulse oximetry. This paper is important as it describes larger cumulative doses of HBOC-201 and longer treatment periods than previously reported. It also demonstrates the role of expanded access in obtaining products for patients with severe anemia [<a href="#rid76">76</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pegylated bovine carboxyhemoglobin</strong> – A 2018 case report described a 42-year-old JW with a lymphoproliferative disorder and gastrointestinal bleeding with a hemoglobin of 3.1 g/dL who was successfully treated over seven days with 6 units of a bovine pegylated carboxyhemoglobin (PCHB, SANGUINATE) [<a href="#rid77">77</a>]. These infusions bridged the patient to interventions such as endoscopy and interventional radiology coil embolization.</p><p></p><p class="bulletIndent1">Other case reports include the successful use of this product in JW patients who underwent liver transplant, cystoprostatectomy and nephrectomy, and gastric bleeding related to nonsteroidal anti-inflammatory drug use [<a href="#rid78">78-80</a>]. </p><p></p><p>These and other studies suggest an encouraging potential role for OCs as oxygen-bridging agents for patients with life-threatening anemia. (See <a class="local">'Hemoglobin-based oxygen carriers'</a> above and  <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion"</a>.)</p><p class="headingAnchor" id="H3119701830"><span class="h2">Process for obtaining OCs</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fclinicaltrials.gov%2F&amp;token=YbJELcAW9G3aZfZrjTwglubdGkNLI6vF%2BUUqouKTYUezNDuyrLCVJ8CPUNOYDvHP&amp;TOPIC_ID=7923" target="_blank">ClinicalTrials.gov</a> site of the US National Institutes of Health (NIH) is an important resource for identifying clinical trials. A standardized format provides the protocol title and category, product name, protocol identifier and status, trial description, inclusion and exclusion criteria, contact information for the manufacturer or principal investigator, and other relevant other information. For OCs, appropriate terms to search include "oxygen carriers," "oxygen therapeutics," "HBOC," "perfluorocarbons," "PFC," and "blood substitutes."</p><p>The process for obtaining a product under the compassionate use category of expanded access (EA) is as follows [<a href="#rid81">81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Contact the manufacturer – Contact information is usually available in the protocol information at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=7923" target="_blank">ClinicalTrials.gov</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contact the FDA Center for Biologics Evaluation and Research (CBER):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Daytime phone number – Direct: 240-402-8020; General (Consumer Affairs): 800-835-4709. </p><p class="bulletIndent2"><span class="glyph">•</span>After-hours emergency number – 866-300-4374. </p><p></p><p class="bulletIndent1">The FDA will work with the manufacturer through an emergency IND (eIND) process.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtain approval from the requesting facility's Institutional Review Board (IRB).</p><p></p><p>The availability of specific OC products via this process varies, and occasionally no products are available under an EA protocol. </p><p>The unlicensed OC HBOC-201-Hemopure (Hemoglobin glutamer-250 [bovine]), a purified, crosslinked, polymerized, acellular bovine hemoglobin manufactured in the United States (see <a class="local">'Hemoglobin-based oxygen carriers'</a> above), is not approved by the FDA, but it is the only HBOC available through FDA EA protocols for special instances of life-threatening anemia in patients for whom allogeneic red blood cell transfusion is not an option, per the process described above [<a href="#rid82">82</a>]. Ongoing clinical trials using HBOC-201 can be reviewed on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=7923" target="_blank">ClinicalTrials.gov</a> website by searching on HBOC-201.</p><p>EA information for other products is available in <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fclinicaltrials.gov%2F&amp;token=YbJELcAW9G3aZfZrjTwglubdGkNLI6vF%2BUUqouKTYUezNDuyrLCVJ8CPUNOYDvHP&amp;TOPIC_ID=7923" target="_blank">ClinicalTrials.gov</a>. If a clinician is familiar with a specific product name, an inquiry can be made regarding whether the product is accessible through an EA.</p><p>Sanguinate is not in clinical trials for life-threatening anemia in patients for whom blood is not an option.</p><p class="headingAnchor" id="H1858233228"><span class="h2">Right to Try</span><span class="headingEndMark"> — </span>The Right to Try Act of 2018 offers another option for certain patients to obtain unlicensed drugs or treatments. Eligible patients are those with a diagnosed life-threatening disease who have exhausted approved treatments and are not qualified to participate in a clinical trial. The process involves consultation of the patient and/or their physician with the manufacturer who will determine whether to make the product available; access processes are sponsor-specific. The FDA does not review or approve Right to Try requests [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H15"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H16"><span class="h2">HBOC-associated side effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasoconstriction</strong> – Vasoconstriction and pressor effects have been described [<a href="#rid84">84-86</a>]. A recognized cause is the scavenging of nitric oxide (NO) by hemoglobin in some OCs [<a href="#rid14">14,87-93</a>]. NO, also called endothelial-derived relaxing factor (EDRF), has vasodilatory properties, and NO scavenging, which decreases its availability to the vasculature, can cause systemic vasoconstriction, decreased blood flow, release of proinflammatory mediators, and loss of platelet inactivation, potentially leading to thrombosis in the heart and/or other organs [<a href="#rid15">15,51,94</a>]. To address this problem, a bovine pegylated carboxylated (PCHB) product (SANGUINATE) was "designed to provide a low-level therapeutic release of carbon monoxide that inhibits vasoconstriction" [<a href="#rid95">95,96</a>]. This product is discussed in more detail above. (See <a class="local">'Hemoglobin-based oxygen carriers'</a> above.)</p><p></p><p class="bulletIndent1">The role of NO in vascular biology and potential adverse effects of NO scavenging are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins", section on 'Nitric oxide transport'</a> and  <a class="medical medical_review" href="/z/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use", section on 'Biology and pharmacokinetics'</a>.)</p><p></p><p class="bulletIndent1">Other proposed mechanisms of vasoconstriction with HBOCs include autoregulatory vasoconstrictive reflex of excess tissue oxygen concentrations, the oxidation properties of hemoglobin as it degrades, an adrenergic effect caused by the direct action of hemoglobin on peripheral nerves, and carrier interaction with endothelin, a regulator of vascular tone [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemostatic effects</strong> – Studies in rabbits showed an increased hemostatic effect of HBOC, perhaps related to reversal of the inhibitory effect of NO on platelet adhesion and aggregation [<a href="#rid98">98,99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GI symptoms</strong> – Reported gastrointestinal (GI) side effects have included nausea, vomiting, diarrhea, dysphagia, bloating, and other symptoms. Symptoms have been reported as mild to moderate and usually not requiring treatment. Lack of availability of NO in GI tissues has been a proposed cause [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunomodulatory effects</strong> – Immunosuppression leading to increased risk of infection was reported in animals, and surveillance for this effect may be warranted in human trials [<a href="#rid101">101,102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Changes in laboratory values</strong> – The adverse effect of HBOCs on laboratory tests has been attributed to the higher plasma hemoglobin concentrations that can occur with infusion of an HBOC. Tests that have yielded inaccurate results in the presence of HBOCs include those for liver enzymes, bilirubin, amylase, and others, including optical assays for coagulation times and troponin levels [<a href="#rid100">100,103,104</a>]. In a 2018 single case study of a patient transfused with HBOC-201, four common chemistry analyzers demonstrated cross-platform variability in multiple assays [<a href="#rid80">80,105</a>]. In one publication, laboratory tests that were not affected by the presence of HBOCs have included electrolytes, glucose, blood gases, creatinine (enzymatic methods), and PT and aPTT (mechanical methods) [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects on survival</strong> – Findings from a seminal meta-analysis that assessed the safety of HBOCs in a total of 3711 patients enrolled in 16 trials involving five different hemoglobin-based OC products contributed to the decline of product development [<a href="#rid15">15</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared with control groups receiving other treatments (allogeneic blood, crystalloids, colloids), those receiving HBOCs had a statistically significant increase in the risk of death following the use of these agents (risk ratio [RR] 1.30, 95% CI 1.05-1.61).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared with controls, patients receiving an HBOC had a significantly increased risk of myocardial infarction (RR 2.71, 95% CI 1.67-4.40).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subgroup analysis indicated that these increased risks were not restricted to a particular HBOC preparation or clinical indication (surgery, stroke, or trauma).</p><p></p><p class="bulletIndent1">An accompanying editorial concluded that, given these findings and the consistency of these results with preclinical evidence of potential toxicity, further trials of HBOCs should not be conducted until it could be shown that these agents were at least as effective in reducing mortality or serious morbidity as the available standards of care [<a href="#rid106">106</a>]. However, HBOCs have subsequently undergone re-assessment, as described below. (See <a class="local">'History of regulation and licensure'</a> below.)</p><p></p><p class="headingAnchor" id="H23"><span class="h2">PFC-associated side effects</span><span class="headingEndMark"> — </span>The major clinical problems associated with perfluorocarbons (PFCs) were flu-like symptoms attributed to cytokine-mediated effects, and platelet sequestration in the spleen and liver, causing hepatosplenomegaly and lowering of the platelet count by as much as 40 percent [<a href="#rid14">14</a>]. </p><p>A comprehensive review of PFCs, clinical trials, and adverse effects summarized commonly reported adverse effects [<a href="#rid107">107</a>]. Other less common effects have also been described [<a href="#rid24">24,41,76</a>]. An industry-sponsored publication from South Africa also summarizes a large experience with PFCs in over 1700 patients [<a href="#rid108">108</a>].</p><p>The requesting physician should carefully review information on adverse effects and recommended treatments provided in the manufacturer's product information or Investigator Brochure.</p><p class="headingAnchor" id="H24"><span class="h1">CHALLENGES</span><span class="headingEndMark"> — </span>Concerns about adverse effects and short intravascular life have hindered regulatory approval for continued research and clinical applicability. Other issues have included supply, cost, and regulatory requirements, as discussed in the following sections.</p><p class="headingAnchor" id="H25"><span class="h2">Supply</span><span class="headingEndMark"> — </span>It is estimated that 70,000 kg of hemoglobin would be required to replace 20 percent of the United States allogeneic red blood cell (RBC) transfusions annually [<a href="#rid109">109</a>]. Limitations on availability, management, and manufacturing of raw materials would present significant HBOC production challenges. </p><p>Two units of RBCs are required to produce one therapeutic HBOC dose as formulated. However, the expiration rate of human blood donated by volunteers is extremely low, making this a truly scarce resource. Furthermore, it is not known whether volunteer blood donors would support the raw materials needs of a commercial biotechnology enterprise. A human hemoglobin-based product, Hemospan (MP40X), would have faced these challenges, but the manufacturer ceased operations due to several factors, including at least one clinical trial that showed higher rates of adverse events than hydroxyethyl starch [<a href="#rid110">110</a>].</p><p>Animal-derived (eg, bovine) hemoglobin requires intensive management of large herds. At a minimum, animal testing and careful herd management is necessary to address possible regulatory or public concerns about contagion from source animals. This concern was compounded by reports that allogeneic transfusion was the likely cause of human-to-human transmission of variant Creutzfeldt-Jakob disease (the human variant of bovine spongiform encephalopathy) [<a href="#rid111">111,112</a>]. (See  <a class="medical medical_review" href="/z/d/html/7950.html" rel="external">"Blood donor screening: Medical history", section on 'CJD and vCJD deferral criteria'</a> and  <a class="medical medical_review" href="/z/d/html/5076.html" rel="external">"Variant Creutzfeldt-Jakob disease", section on 'Bovine spongiform encephalopathy'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Cost</span><span class="headingEndMark"> — </span>Manufacturers of HBOCs are prohibited by federal regulations to discuss pricing information for products under development or in clinical trials. Given other challenges facing OC manufacturers, the market potential may be limited unless the price of an RBC unit-equivalent eventually approached that of an allogeneic RBC unit, which is approximately $300 to $400 USD, including crossmatching and other costs. Two earlier HBOC price estimates ranged from $400 to $800 USD per unit [<a href="#rid113">113,114</a>].</p><p class="headingAnchor" id="H27"><span class="h2">History of regulation and licensure</span><span class="headingEndMark"> — </span>Like other pharmaceuticals and biologics, OCs must meet US Food and Drug Administration (FDA) safety and efficacy requirements to obtain approval. </p><p>Since 1991, the FDA has been communicating safety and efficacy expectations to the biotechnology community [<a href="#rid115">115,116</a>]. In late 1999, the agency conducted a workshop with the National Institutes of Health that comprehensively addressed possible clinical uses for OCs [<a href="#rid117">117</a>]. These documents provide important insights into the thinking and expectations of the FDA at that time.</p><p>Optimism in the early 2000s about near-term approval of OCs was dampened by the discontinuation of research into the use of crosslinked hemoglobin after a trial of a diaspirin crosslinked hemoglobin OC (HemAssist) showed a higher mortality rate in recipients of the OC versus controls [<a href="#rid21">21,118</a>]. Efforts to advance recombinant product trials were discontinued because of reported adverse effects [<a href="#rid118">118</a>]. Following the outcome of the HemeAssist trial, the FDA expanded the clinical testing requirements for all similar products, causing a deceleration in trial approval [<a href="#rid119">119,120</a>]. (See <a class="local">'Hemorrhagic shock'</a> above.)</p><p>In 2006, the National Heart, Lung, and Blood Institute (NHLBI) convened a workshop to evaluate scientific issues that were critical to developing HBOCs [<a href="#rid121">121</a>]. Concerns about adverse cardiovascular events resulted in the development of recommendations for basic research that would be critical for developing safer products. </p><p>In 2017, a plan to resume HBOC development and evaluate new clinical trial protocols was discussed at a joint meeting of the FDA, NIH, and Department of Defense. Possible outcomes may be an increase in oxygen therapeutics research and development; approval of new clinical trials may occur at a faster pace than that observed in the past several years [<a href="#rid108">108</a>]. </p><p>Blood shortages during the COVID-19 pandemic have further increased interest. (See <a class="local">'History of OC development'</a> above.)</p><p class="headingAnchor" id="H999930707"><span class="h1">OTHER PRODUCTS UNDER DEVELOPMENT</span></p><p class="headingAnchor" id="H2581633353"><span class="h2">In vitro RBC production or modification</span></p><p class="headingAnchor" id="H2964371872"><span class="h2">Cell culture</span><span class="headingEndMark"> — </span>Advances in cellular engineering have made it possible to culture red blood cells (RBCs) <em>in vitro</em> from hematopoietic progenitor cells, which may represent an exciting, viable approach to meeting global red blood cell transfusion needs. Potential sources of hematopoietic progenitor cells include umbilical cord blood, adult peripheral blood, multipotent stem cells, and immortalized adult erythroid progenitor cells [<a href="#rid122">122</a>].</p><p>In a proof of principle study in mice and a human volunteer, transfused RBCs cultured from autologous CD34 cells demonstrated attributes consistent with endogenous RBCs such as oxygen binding and release, deformability, enzyme content, expression of ABO antigens, and viability [<a href="#rid123">123</a>]. This is an exciting step, but considerable challenges to the large-scale production of RBCs for therapeutic transfusion purposes exist, including significant biologic, regulatory, funding, and logistic issues.</p><p class="headingAnchor" id="H737680782"><span class="h2">Elimination of blood group antigens</span><span class="headingEndMark"> — </span>Group O blood can be administered to individuals of any ABO blood type. (See  <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">"Pretransfusion testing for red blood cell transfusion", section on 'Blood type (ABO and RhD type)'</a>.)</p><p>Enzymatic conversion of type A, B, and AB RBCs to group O has been achieved in vitro via the use of exoglycosidases derived from bacterial sources [<a href="#rid124">124</a>]. This enzymatic conversion (ECO) technique, if proven to be safe and effective, has the potential to simplify transfusion by eliminating the risk for ABO-incompatible transfusion errors and creating a more universal RBC inventory [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H836047160"><span class="h2">Other emerging products</span><span class="headingEndMark"> — </span>Examples of additional OCs that are under development but are not found in ClinicalTrials.gov include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ErythroMER</strong> – ErythroMER is described as an encapsulated hemoglobin-based "deformable cross-linked polymeric nanoparticle"; development is being supported by the National Institutes of Health and the US Department of Defense [<a href="#rid126">126,127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HemoACT</strong> – HemoACT is a human hemoglobin linked with human albumin [<a href="#rid128">128</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxyvita</strong> – Oxyvita is a liposome-encapsulated, polymerized bovine hemoglobin in which increased polymerization creates a large macromolecule [<a href="#rid129">129,130</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vidaphor</strong> – Vidaphor (formerly Perftoran) is a perfluorocarbon that has been used for an estimated 35,000 infusions in Russia and other countries outside the United States [<a href="#rid29">29,131</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin vesicles </strong>– Hemoglobin vesicles (HbVs) contain a purified concentrated solution of human hemoglobin prepared from outdated donated blood and encapsulated in PEGylated lysosomes; they have been tested in a small human safety study in Japan [<a href="#rid132">132</a>].</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uses for oxygen carriers (OCs)</strong> – OCs are developed as alternatives to red blood cell (RBC) transfusions. The clinical areas for which OCs originally appeared to have potential were hemorrhagic shock related to trauma with acute blood loss and elective cardiac surgery. However, the focus has shifted to the use of hemoglobin-based oxygen carriers (HBOCs) as oxygen-bridging agents for situations in which blood is not an option (BNAO) or blood is unavailable due to incompatibility. (See <a class="local">'History of OC development'</a> above and <a class="local">'Potential uses for OCs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Features needed for an OC</strong> – An ideal substance for carrying and delivering oxygen would have properties similar to RBCs, as well as a long shelf life, cost effectiveness, and minimal side effects. (See <a class="local">'Characteristics of an ideal OC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Categories of products</strong> – Two major categories of OCs that have been developed and evaluated are HBOCs and perfluorocarbons (PFCs). Research on PFCs appears to be primarily focused on diagnostic applications and other clinical uses rather than as an alternative to RBC transfusion. (See <a class="local">'Categories of oxygen carriers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Availability</strong> – No OCs are licensed by the US Food and Drug Administration (FDA) for routine use; Hemopure is an HBOC available under expanded access for individuals with severe anemia. The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fclinicaltrials.gov%2F&amp;token=YbJELcAW9G3aZfZrjTwglubdGkNLI6vF%2BUUqouKTYUezNDuyrLCVJ8CPUNOYDvHP&amp;TOPIC_ID=7923" target="_blank">ClinicalTrials.gov</a> website and several FDA resources provide information for these potentially life-preserving products. (See <a class="local">'Resources and processes for obtaining OCs in the United States'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Major side effects reported for HBOCs have included (but are not limited to) vasoactivity and gastrointestinal symptoms. Supply and cost issues also may present challenges. (See <a class="local">'Adverse effects'</a> above and <a class="local">'Challenges'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional approaches under investigation</strong> – New ideas for HBOCs and methods for generating or modifying RBCs in vitro are being pursued. (See <a class="local">'Other products under development'</a> above.)</p><p></p><p class="headingAnchor" id="H534322845"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges extensive contributions of Arthur J Silvergleid, MD to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Winslow RM. Blood substitutes: refocusing an elusive goal. Br J Haematol 2000; 111:387.</a></li><li><a class="nounderline abstract_t">Stowell CP, Levin J, Spiess BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion 2001; 41:287.</a></li><li><a class="nounderline abstract_t">Reid TJ. Hb-based oxygen carriers: are we there yet? Transfusion 2003; 43:280.</a></li><li><a class="nounderline abstract_t">Fakhry SM, Sheldon GF. Blood administration, risks, and substitutes. Adv Surg 1995; 28:71.</a></li><li class="breakAll">Baxter Healthcare Corp. Company information.</li><li><a class="nounderline abstract_t">AMBERSON WR, JENNINGS JJ, RHODE CM. Clinical experience with hemoglobin-saline solutions. J Appl Physiol 1949; 1:469.</a></li><li class="breakAll">AABB Weekly Report. July 28, 2000.</li><li><a class="nounderline abstract_t">Marwick C. More than a trickle of interest in blood substitutes. JAMA 1994; 271:895.</a></li><li><a class="nounderline abstract_t">Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994; 34:464.</a></li><li class="breakAll">Winslow RM. Red cell substitutes: Impact of blood substitutes worldwide. Annual Meeting Compendium. American Association of Blood Banks, Bethesda 1999.</li><li><a class="nounderline abstract_t">Weiskopf RB, Glassberg E, Guinn NR, et al. The need for an artificial oxygen carrier for disasters and pandemics, including COVID-19. Transfusion 2020; 60:3039.</a></li><li class="breakAll">SEC charges Massachusetts biotechnology company and executives with securities fraud. US Securities and Exchange Commission. Litigation Release No. 19376, 9/14/05.</li><li><a class="nounderline abstract_t">Burton TM. Amid alarm bells, a blood substitute keeps pumping. Wall Street Journal 2006; 247:1.</a></li><li><a class="nounderline abstract_t">Scott MG, Kucik DF, Goodnough LT, Monk TG. Blood substitutes: evolution and future applications. Clin Chem 1997; 43:1724.</a></li><li><a class="nounderline abstract_t">Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008; 299:2304.</a></li><li><a class="nounderline abstract_t">Jahr JS, Moallempour M, Lim JC. HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation). Expert Opin Biol Ther 2008; 8:1425.</a></li><li><a class="nounderline abstract_t">Klein HG. The prospects for red-cell substitutes. N Engl J Med 2000; 342:1666.</a></li><li><a class="nounderline abstract_t">Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg 1996; 82:390.</a></li><li><a class="nounderline abstract_t">Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol 2003; 285:H1411.</a></li><li><a class="nounderline abstract_t">Lamy ML, Daily EK, Brichant JF, et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology 2000; 92:646.</a></li><li><a class="nounderline abstract_t">Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282:1857.</a></li><li><a class="nounderline abstract_t">Kerner T, Ahlers O, Veit S, et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study. Intensive Care Med 2003; 29:378.</a></li><li><a class="nounderline abstract_t">Abuchowski A. PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients. Adv Exp Med Biol 2016; 876:461.</a></li><li><a class="nounderline abstract_t">Gupta AS. 2017 Military Supplement: Hemoglobin-based Oxygen Carriers: Current State-of-the-Art and Novel Molecules. Shock 2017.</a></li><li><a class="nounderline abstract_t">Rollwagen FM, Gafney WC, Pacheco ND, et al. Multiple responses to administration of liposome-encapsulated hemoglobin (LEH): Effects on hematopoiesis and serum IL-6 levels. Exp Hematol 1996; 24:429.</a></li><li><a class="nounderline abstract_t">Szebeni J, Wassef NM, Hartman KR, et al. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 1997; 37:150.</a></li><li><a class="nounderline abstract_t">Rudolph AS, Cliff R, Kwasiborski V, et al. Liposome-encapsulated hemoglobin modulates lipopolysaccharide-induced tumor necrosis factor-alpha production in mice. Crit Care Med 1997; 25:460.</a></li><li><a class="nounderline abstract_t">Coll-Satue C, Bishnoi S, Chen J, Hosta-Rigau L. Stepping stones to the future of haemoglobin-based blood products: clinical, preclinical and innovative examples. Biomater Sci 2021; 9:1135.</a></li><li><a class="nounderline abstract_t">Jahr JS, Guinn NR, Lowery DR, et al. Blood Substitutes and Oxygen Therapeutics: A Review. Anesth Analg 2021; 132:119.</a></li><li><a class="nounderline abstract_t">Ferenz KB, Steinbicker AU. Artificial Oxygen Carriers-Past, Present, and Future-a Review of the Most Innovative and Clinically Relevant Concepts. J Pharmacol Exp Ther 2019; 369:300.</a></li><li><a class="nounderline abstract_t">Siegel JH, Fabian M, Smith JA, Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock. J Trauma 1997; 42:199.</a></li><li><a class="nounderline abstract_t">Thompson A, McGarry AE, Valeri CR, Lieberthal W. Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J Appl Physiol (1985) 1994; 77:2348.</a></li><li><a class="nounderline abstract_t">Olson JS, Foley EW, Rogge C, et al. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004; 36:685.</a></li><li><a class="nounderline abstract_t">Charbe NB, Castillo F, Tambuwala MM, et al. A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers. Blood Rev 2022; 54:100927.</a></li><li><a class="nounderline abstract_t">Clark LC Jr, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152:1755.</a></li><li><a class="nounderline abstract_t">Keipert PE, Faithfull NS, Bradley JD, et al. Enhanced oxygen delivery by perflubron emulsion during acute hemodilution. Artif Cells Blood Substit Immobil Biotechnol 1994; 22:1161.</a></li><li><a class="nounderline abstract_t">Kerins DM. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Am J Med Sci 1994; 307:218.</a></li><li><a class="nounderline abstract_t">Spahn DR, Waschke KF, Standl T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 2002; 97:1338.</a></li><li class="breakAll">"Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial." Stern Investor Relations. Business Wire. September 11, 2014.</li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT00174980.</li><li><a class="nounderline abstract_t">Khan F, Singh K, Friedman MT. Artificial Blood: The History and Current Perspectives of Blood Substitutes. Discoveries (Craiova) 2020; 8:e104.</a></li><li><a class="nounderline abstract_t">Ketcham EM, Cairns CB. Hemoglobin-based oxygen carriers: development and clinical potential. Ann Emerg Med 1999; 33:326.</a></li><li><a class="nounderline abstract_t">LaMuraglia GM, O'Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg 2000; 31:299.</a></li><li class="breakAll">Hemosol, Inc. Company announcement. July 2000.</li><li><a class="nounderline abstract_t">Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998; 187:113.</a></li><li><a class="nounderline abstract_t">Young JS, Fernandez M, Meredith JW. The effect of oxygen delivery-directed resuscitation on splanchnic and hepatic oxygen transport after hemorrhagic shock. J Surg Res 1997; 71:87.</a></li><li><a class="nounderline abstract_t">Knudson MM, Bermudez KM, Doyle CA, et al. Use of tissue oxygen tension measurements during resuscitation from hemorrhagic shock. J Trauma 1997; 42:608.</a></li><li><a class="nounderline abstract_t">DeAngeles DA, Scott AM, McGrath AM, et al. Resuscitation from hemorrhagic shock with diaspirin cross-linked hemoglobin, blood, or hetastarch. J Trauma 1997; 42:406.</a></li><li><a class="nounderline abstract_t">Herschman Z, Cardoso R, Mazur W. Perfluorochemical emulsion for resuscitation of experimental hemorrhagic shock. Crit Care Med 1995; 23:785.</a></li><li><a class="nounderline abstract_t">Kochetygov NI, Gorkoun AV, Gerbut KA, et al. Study of therapeutic efficiency of new blood substitutes in experimental hemorrhagic shock. Artif Cells Blood Substit Immobil Biotechnol 1996; 24:685.</a></li><li><a class="nounderline abstract_t">Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293:1653.</a></li><li><a class="nounderline abstract_t">Dalton R. Trauma trials leave ethicists uneasy. Nature 2006; 440:390.</a></li><li><a class="nounderline abstract_t">Holloway KF. Accidental communities: race, emergency medicine, and the problem of polyheme. Am J Bioeth 2006; 6:7.</a></li><li><a class="nounderline abstract_t">Karlawish JH, Hall JB. The controversy over emergency research. A review of the issues and suggestions for a resolution. Am J Respir Crit Care Med 1996; 153:499.</a></li><li><a class="nounderline abstract_t">Gannon CJ, Napolitano LM. Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies. Crit Care Med 2002; 30:1893.</a></li><li><a class="nounderline abstract_t">Marelli TR. Use of a hemoglobin substitute in the anemic Jehovah's Witness patient. Crit Care Nurse 1994; 14:31.</a></li><li><a class="nounderline abstract_t">Cothren C, Moore EE, Offner PJ, et al. Blood substitute and erythropoietin therapy in a severely injured Jehovah's witness. N Engl J Med 2002; 346:1097.</a></li><li><a class="nounderline abstract_t">Anton N, Hitzler JK, Kavanagh BP. Treatment of life-threatening post-haemorrhagic anaemia with cell-free haemoglobin solution in an adolescent Jehovah's Witness. Br J Haematol 2002; 118:1183.</a></li><li><a class="nounderline abstract_t">Lanzkron S, Moliterno AR, Norris EJ, et al. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion 2002; 42:1422.</a></li><li><a class="nounderline abstract_t">Lanzinger MJ, Niklason LE, Shannon M, Hill SE. Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth 2005; 52:369.</a></li><li><a class="nounderline abstract_t">Cothren CC, Moore EE, Long JS, et al. Large volume polymerized haemoglobin solution in a Jehovah's Witness following abruptio placentae. Transfus Med 2004; 14:241.</a></li><li><a class="nounderline abstract_t">Agrawal YP, Freedman M, Szczepiorkowski ZM. Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report. Transfusion 2005; 45:1735.</a></li><li><a class="nounderline abstract_t">McConachie SM, Almadrahi Z, Wahby KA, Wilhelm SM. Pharmacotherapy in Acutely Anemic Jehovah's Witnesses: An Evidence-Based Review. Ann Pharmacother 2018; 52:910.</a></li><li><a class="nounderline abstract_t">Barrett CD, Theodore S, Dechert T, et al. Resuscitation of an exsanguinated obstetrics patient with HBOC-201: A case report. Transfusion 2022; 62 Suppl 1:S218.</a></li><li><a class="nounderline abstract_t">Mullon J, Giacoppe G, Clagett C, et al. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 2000; 342:1638.</a></li><li><a class="nounderline abstract_t">Unnikrishnan A, Pelletier JPR, Bari S, et al. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Transfusion 2019; 59:1907.</a></li><li><a class="nounderline abstract_t">Marinaro J, Smith J, Tawil I, et al. HBOC-201 use in traumatic brain injury: case report and review of literature. Transfusion 2009; 49:2054.</a></li><li><a class="nounderline abstract_t">Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 2010; 50:1561.</a></li><li><a class="nounderline abstract_t">Gonzalez P, Hackney AC, Jones S, et al. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J Investig Med 1997; 45:258.</a></li><li><a class="nounderline abstract_t">Kaul DK, Liu X, Nagel RL. Ameliorating effects of fluorocarbon emulsion on sickle red blood cell-induced obstruction in an ex vivo vasculature. Blood 2001; 98:3128.</a></li><li><a class="nounderline abstract_t">Raff JP, Dobson CE, Tsai HM. Transfusion of polymerised human haemoglobin in a patient with severe sickle-cell anaemia. Lancet 2002; 360:464.</a></li><li class="breakAll">Stover R. A New Generation of Oxygen Therapeutics. Stover and Associates; LLC; Stamford, CT 1996.</li><li><a class="nounderline abstract_t">Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 2010; 50:1561.</a></li><li><a class="nounderline abstract_t">Jordan SD, Alexander E. Bovine hemoglobin: a nontraditional approach to the management of acute anemia in a Jehovah's Witness patient with autoimmune hemolytic anemia. J Pharm Pract 2013; 26:257.</a></li><li><a class="nounderline abstract_t">Davis JM, El-Haj N, Shah NN, et al. Use of the blood substitute HBOC-201 in critically ill patients during sickle crisis: a three-case series. Transfusion 2018; 58:132.</a></li><li><a class="nounderline abstract_t">Zumberg M, Gorlin J, Griffiths EA, et al. A case study of 10 patients administered HBOC-201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option. Transfusion 2020; 60:932.</a></li><li><a class="nounderline abstract_t">DeSimone RA, Berlin DA, Avecilla ST, Goss CA. Investigational use of PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with hemorrhagic shock. Transfusion 2018; 58:2297.</a></li><li><a class="nounderline abstract_t">Holzner ML, DeMaria S, Haydel B, et al. Pegylated Bovine Carboxyhemoglobin (SANGUINATE) in a Jehovah's Witness Undergoing Liver Transplant: A Case Report. Transplant Proc 2018; 50:4012.</a></li><li><a class="nounderline abstract_t">Brotman I, Kocher M, McHugh S. Bovine Hemoglobin-Based Oxygen Carrier Treatment in a Severely Anemic Jehovah's Witness Patient After Cystoprostatectomy and Nephrectomy: A Case Report. A A Pract 2019; 12:243.</a></li><li><a class="nounderline abstract_t">Bachert SE, Dogra P, Boral LI. Alternatives to Transfusion. Am J Clin Pathol 2020; 153:287.</a></li><li class="breakAll">https://www.fda.gov/ForPatients/Other/default.htm (Accessed on April 11, 2017).</li><li class="breakAll">http://www.fda.gov/newsevents/publichealthfocus/expandedaccesscompassionateuse/ucm429624.htm (Accessed on November 23, 2018).</li><li class="breakAll">Right try. US Food and Drug Administration. Available at: www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try (Accessed on March 11, 2022).</li><li><a class="nounderline abstract_t">Cabrales P, Tsai AG, Intaglietta M. Balance between vasoconstriction and enhanced oxygen delivery. Transfusion 2008; 48:2087.</a></li><li><a class="nounderline abstract_t">Cabrales P. Low oxygen-affinity hemoglobin solution increases oxygenation of partially ischemic tissue during acute anemia. J Am Coll Surg 2010; 210:271.</a></li><li><a class="nounderline abstract_t">Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008; 64:1484.</a></li><li><a class="nounderline abstract_t">Buehler PW, Alayash AI. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems. Transfusion 2004; 44:1516.</a></li><li><a class="nounderline abstract_t">Sanders KE, Ackers G, Sligar S. Engineering and design of blood substitutes. Curr Opin Struct Biol 1996; 6:534.</a></li><li><a class="nounderline abstract_t">Patel RP. Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes. Free Radic Biol Med 2000; 28:1518.</a></li><li><a class="nounderline abstract_t">Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003; 348:1483.</a></li><li><a class="nounderline abstract_t">Tsai AG, Cabrales P, Manjula BN, et al. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood 2006; 108:3603.</a></li><li><a class="nounderline abstract_t">Ritchie AJ, Hartshorn S, Crosbie AE, et al. The action of diaspirin cross-linked haemoglobin blood substitute on human arterial bypass conduits. Eur J Cardiothorac Surg 2000; 18:241.</a></li><li><a class="nounderline abstract_t">Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383.</a></li><li><a class="nounderline abstract_t">De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96:60.</a></li><li class="breakAll">http://www.prolongpharma.com/sanguinate/.</li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT02754999.</li><li><a class="nounderline abstract_t">Gulati A, Sharma AC, Singh G. Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Crit Care Med 1996; 24:137.</a></li><li><a class="nounderline abstract_t">Lee DH, Bardossy L, Peterson N, Blajchman MA. o-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits. Blood 2000; 96:3630.</a></li><li><a class="nounderline abstract_t">Simon DI, Stamler JS, Loh E, et al. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26:339.</a></li><li><a class="nounderline abstract_t">Mer M, Hodgson E, Wallis L, et al. Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients. Transfusion 2016; 56:2631.</a></li><li><a class="nounderline abstract_t">Griffiths E, Cortes A, Gilbert N, et al. Haemoglobin-based blood substitutes and sepsis. Lancet 1995; 345:158.</a></li><li><a class="nounderline abstract_t">Langermans JA, Bleeker WK. Haemoglobin-based blood substitutes and infection. Lancet 1995; 345:863.</a></li><li><a class="nounderline abstract_t">Ma Z, Monk TG, Goodnough LT, et al. Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 1997; 43:1732.</a></li><li><a class="nounderline abstract_t">Estep TN. Issues in the development of hemoglobin based oxygen carriers. Semin Hematol 2019; 56:257.</a></li><li><a class="nounderline abstract_t">Korte EA, Pozzi N, Wardrip N, et al. Analytical interference of HBOC-201 (Hemopure, a synthetic hemoglobin-based oxygen carrier) on four common clinical chemistry platforms. Clin Chim Acta 2018; 482:33.</a></li><li><a class="nounderline abstract_t">Fergusson DA, McIntyre L. The future of clinical trials evaluating blood substitutes. JAMA 2008; 299:2324.</a></li><li><a class="nounderline abstract_t">Castro CI, Briceno JC. Perfluorocarbon-based oxygen carriers: review of products and trials. Artif Organs 2010; 34:622.</a></li><li><a class="nounderline abstract_t">Mackenzie CF, Dubé GP, Pitman A, Zafirelis M. Users Guide to Pitfalls and Lessons Learned About HBOC-201 During Clinical Trials, Expanded Access, and Clinical Use in 1,701 Patients. Shock 2019; 52:92.</a></li><li><a class="nounderline abstract_t">Kumar R. Recombinant hemoglobins as blood substitutes: a biotechnology perspective. Proc Soc Exp Biol Med 1995; 208:150.</a></li><li><a class="nounderline abstract_t">Olofsson CI, Górecki AZ, Dirksen R, et al. Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study. Anesthesiology 2011; 114:1048.</a></li><li><a class="nounderline abstract_t">Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417.</a></li><li><a class="nounderline abstract_t">Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527.</a></li><li class="breakAll">Winslow RM. New Frontiers in Transfusion Medicine 1995. American Association of Blood Banks Teleconference.</li><li><a class="nounderline abstract_t">Biopure Hemopure new. Pharmaceutical Approvals Monthly. F-D-C Reports 2003; 8:6.</a></li><li><a class="nounderline abstract_t">Points to consider in the safety evaluation of hemoglobin-based oxygen carriers. Center for Biologics Evaluation and Research. Transfusion 1991; 31:369.</a></li><li><a class="nounderline abstract_t">Points to consider on efficacy evaluation of hemoglobin- and perfluorocarbon-based oxygen carriers. Center for Biologics Evaluation and Research. Transfusion 1994; 34:712.</a></li><li class="breakAll">Oxygen Therapeutics as Blood Substitutes. FDA Workshop, September 1999.</li><li><a class="nounderline abstract_t">Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des 2005; 11:4099.</a></li><li class="breakAll">Davis R. Blood substitute may be anticipated break. USA Today. June 20, 2000.</li><li class="breakAll">Blood, sweat and hemoglobin: The long halting search for artificial blood takes some new twists. HeadsUp, Newsedge Corporation, Burlington, 1999.</li><li><a class="nounderline abstract_t">Estep T, Bucci E, Farmer M, et al. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 2008; 48:776.</a></li><li><a class="nounderline abstract_t">Trakarnsanga K, Griffiths RE, Wilson MC, et al. An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells. Nat Commun 2017; 8:14750.</a></li><li><a class="nounderline abstract_t">Giarratana MC, Rouard H, Dumont A, et al. Proof of principle for transfusion of in vitro-generated red blood cells. Blood 2011; 118:5071.</a></li><li><a class="nounderline abstract_t">Olsson ML, Clausen H. Modifying the red cell surface: towards an ABO-universal blood supply. Br J Haematol 2008; 140:3.</a></li><li><a class="nounderline abstract_t">Bagnis C, Chiaroni J, Bailly P. Elimination of blood group antigens: hope and reality. Br J Haematol 2011; 152:392.</a></li><li><a class="nounderline abstract_t">Pan D, Rogers S, Misra S, et al. Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and In Vivo Efficacy Results. Blood 2016; 128:1027.</a></li><li class="breakAll">https://www.sbir.gov/sbirsearch/detail/1305067 (Accessed on June 10, 2020).</li><li><a class="nounderline abstract_t">Haruki R, Kimura T, Iwasaki H, et al. Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute. Sci Rep 2015; 5:12778.</a></li><li><a class="nounderline abstract_t">Harrington JP, Wollocko H. Pre-clinical studies using OxyVita hemoglobin, a zero-linked polymeric hemoglobin: a review. J Artif Organs 2010; 13:183.</a></li><li><a class="nounderline abstract_t">Harrington JP, Wollocko H. Molecular Design Properties of OxyVita Hemoglobin, a New Generation Therapeutic Oxygen Carrier: A Review. J Funct Biomater 2011; 2:414.</a></li><li><a class="nounderline abstract_t">Latson GW. Perftoran (Vidaphor)-Introduction to Western Medicine. Shock 2019; 52:65.</a></li><li><a class="nounderline abstract_t">Azuma H, Amano T, Kamiyama N, et al. First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative. Blood Adv 2022; 6:5711.</a></li></ol></div><div id="topicVersionRevision">Topic 7923 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122077" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Blood substitutes: refocusing an elusive goal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11239237" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Progress in the development of RBC substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559026" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hb-based oxygen carriers: are we there yet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7879691" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blood administration, risks, and substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7879691" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Blood administration, risks, and substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18104040" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical experience with hemoglobin-saline solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18104040" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical experience with hemoglobin-saline solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120947" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : More than a trickle of interest in blood substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023386" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiology of blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023386" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32978804" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The need for an artificial oxygen carrier for disasters and pandemics, including COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32978804" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The need for an artificial oxygen carrier for disasters and pandemics, including COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Amid alarm bells, a blood substitute keeps pumping</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9299967" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Blood substitutes: evolution and future applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443023" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18694360" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10833216" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The prospects for red-cell substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561348" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Blood substitutes: fluids, drugs, or miracle solutions?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12805024" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10719942" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573278" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12541156" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26782246" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968286" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 2017 Military Supplement: Hemoglobin-based Oxygen Carriers: Current State-of-the-Art and Novel Molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8599972" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multiple responses to administration of liposome-encapsulated hemoglobin (LEH): Effects on hematopoiesis and serum IL-6 levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9051089" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118663" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Liposome-encapsulated hemoglobin modulates lipopolysaccharide-induced tumor necrosis factor-alpha production in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33350411" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Stepping stones to the future of haemoglobin-based blood products: clinical, preclinical and innovative examples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30925560" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Blood Substitutes and Oxygen Therapeutics: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30837280" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Artificial Oxygen Carriers-Past, Present, and Future-a Review of the Most Innovative and Clinically Relevant Concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9042870" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7868454" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990349" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : No scavenging and the hypertensive effect of hemoglobin-based blood substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35094845" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5938414" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849918" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Enhanced oxygen delivery by perflubron emulsion during acute hemodilution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8160713" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12459658" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12459658" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12459658" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32309621" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Artificial Blood: The History and Current Perspectives of Blood Substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10036348" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hemoglobin-based oxygen carriers: development and clinical potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10664499" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10664499" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704955" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9271283" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of oxygen delivery-directed resuscitation on splanchnic and hepatic oxygen transport after hemorrhagic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137246" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of tissue oxygen tension measurements during resuscitation from hemorrhagic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9095107" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Resuscitation from hemorrhagic shock with diaspirin cross-linked hemoglobin, blood, or hetastarch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7712774" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Perfluorochemical emulsion for resuscitation of experimental hemorrhagic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922235" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Study of therapeutic efficiency of new blood substitutes in experimental hemorrhagic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811985" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554766" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Trauma trials leave ethicists uneasy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754440" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Accidental communities: race, emergency medicine, and the problem of polyheme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8564087" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The controversy over emergency research. A review of the issues and suggestions for a resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12163811" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8194324" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of a hemoglobin substitute in the anemic Jehovah's Witness patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932486" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Blood substitute and erythropoietin therapy in a severely injured Jehovah's witness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199805" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of life-threatening post-haemorrhagic anaemia with cell-free haemoglobin solution in an adolescent Jehovah's Witness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421214" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Polymerized human Hb use in acute chest syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814750" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180817" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Large volume polymerized haemoglobin solution in a Jehovah's Witness following abruptio placentae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16271098" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29592539" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pharmacotherapy in Acutely Anemic Jehovah's Witnesses: An Evidence-Based Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748693" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Resuscitation of an exsanguinated obstetrics patient with HBOC-201: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10836875" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30768787" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19497051" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : HBOC-201 use in traumatic brain injury: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456679" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9249998" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11698300" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ameliorating effects of fluorocarbon emulsion on sickle red blood cell-induced obstruction in an ex vivo vasculature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241723" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Transfusion of polymerised human haemoglobin in a patient with severe sickle-cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241723" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Transfusion of polymerised human haemoglobin in a patient with severe sickle-cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456679" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869910" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Bovine hemoglobin: a nontraditional approach to the management of acute anemia in a Jehovah's Witness patient with autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29076161" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Use of the blood substitute HBOC-201 in critically ill patients during sickle crisis: a three-case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358832" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A case study of 10 patients administered HBOC-201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30203845" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Investigational use of PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with hemorrhagic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30577305" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pegylated Bovine Carboxyhemoglobin (SANGUINATE) in a Jehovah's Witness Undergoing Liver Transplant: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30272592" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bovine Hemoglobin-Based Oxygen Carrier Treatment in a Severely Anemic Jehovah's Witness Patient After Cystoprostatectomy and Nephrectomy: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31678985" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Alternatives to Transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31678985" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Alternatives to Transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31678985" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Alternatives to Transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31678985" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Alternatives to Transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18631171" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Balance between vasoconstriction and enhanced oxygen delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20193889" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Low oxygen-affinity hemoglobin solution increases oxygenation of partially ischemic tissue during acute anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18545113" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383027" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794165" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Engineering and design of blood substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10927176" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686706" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hemoglobin and the paracrine and endocrine functions of nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16857991" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10925237" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The action of diaspirin cross-linked haemoglobin blood substitute on human arterial bypass conduits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12426562" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7542286" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7542286" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7542286" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565519" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11071664" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : o-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475061" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of nitric oxide synthase inhibition on bleeding time in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27658499" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7823671" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Haemoglobin-based blood substitutes and sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7898253" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Haemoglobin-based blood substitutes and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9299968" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31836032" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Issues in the development of hemoglobin based oxygen carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29580857" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Analytical interference of HBOC-201 (Hemopure, a synthetic hemoglobin-based oxygen carrier) on four common clinical chemistry platforms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443022" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The future of clinical trials evaluating blood substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20698841" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Perfluorocarbon-based oxygen carriers: review of products and trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29076972" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Users Guide to Pitfalls and Lessons Learned About HBOC-201 During Clinical Trials, Expanded Access, and Clinical Use in 1,701 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7831347" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Recombinant hemoglobins as blood substitutes: a biotechnology perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21455059" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962520" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302196" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302196" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Pharmaceutical Approvals Monthly</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2021002" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Points to consider in the safety evaluation of hemoglobin-based oxygen carriers. Center for Biologics Evaluation and Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8073490" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Points to consider on efficacy evaluation of hemoglobin- and perfluorocarbon-based oxygen carriers. Center for Biologics Evaluation and Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8073490" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Points to consider on efficacy evaluation of hemoglobin- and perfluorocarbon-based oxygen carriers. Center for Biologics Evaluation and Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16378514" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Artificial O2 carriers: status in 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16378514" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Artificial O2 carriers: status in 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16378514" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Artificial O2 carriers: status in 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18194373" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28290447" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21885599" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Proof of principle for transfusion of in vitro-generated red blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17970801" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Modifying the red cell surface: towards an ABO-universal blood supply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21210778" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Elimination of blood group antigens: hope and reality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and In Vivo Efficacy Results</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and In Vivo Efficacy Results</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26220366" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21127928" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Pre-clinical studies using OxyVita hemoglobin, a zero-linked polymeric hemoglobin: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24956452" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Molecular Design Properties of OxyVita Hemoglobin, a New Generation Therapeutic Oxygen Carrier: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189604" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Perftoran (Vidaphor)-Introduction to Western Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35939788" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
